Siwen Hu-Lieskovan Selected Research

Siwen Hu-Lieskovan Research Topics

Disease

43	Neoplasms (Cancer) 02/2024 - 06/2005
27	Melanoma (Melanoma, Malignant) 01/2024 - 07/2014
3	Disease Progression 03/2023 - 09/2016
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 01/2019
3	Neoplasm Metastasis (Metastasis) 12/2021 - 11/2018
2	Colonic Neoplasms (Colon Cancer) 10/2016 - 08/2011
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2024
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2023
1	Squamous Cell Carcinoma of Head and Neck 10/2022
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2022
1	Brain Neoplasms (Brain Tumor) 12/2021
1	Tuberculosis (Tuberculoses) 06/2021
1	Immune System Diseases (Immune Disorders) 06/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 10/2020
1	Sarcoma (Soft Tissue Sarcoma) 01/2019
1	Testicular Neoplasms (Testicular Cancer) 11/2018
1	Colorectal Neoplasms (Colorectal Cancer) 01/2018
1	Rectal Neoplasms (Rectal Cancer) 08/2011
1	Ewing Sarcoma (Sarcoma, Ewing) 10/2005
1	Rhabdomyosarcoma 06/2005

Drug/Important Bio-Agent (IBA)

12	Immune Checkpoint InhibitorsIBA 02/2024 - 03/2016
6	Biomarkers (Surrogate Marker)IBA 05/2022 - 01/2017
5	pembrolizumabIBA 03/2023 - 09/2016
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2021 - 03/2015
5	LigandsIBA 11/2021 - 10/2005
5	AntibodiesIBA 06/2021 - 07/2016
4	NivolumabIBA 06/2023 - 12/2019
4	InterferonsIBA 06/2023 - 01/2017
4	IpilimumabIBA 06/2023 - 01/2019
4	AntigensIBA 01/2020 - 03/2015
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 04/2020
3	Programmed Cell Death 1 ReceptorIBA 01/2021 - 10/2016
2	RNA (Ribonucleic Acid)IBA 06/2023 - 11/2021
2	utomilumabIBA 10/2022 - 09/2017
2	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 08/2011
2	VaccinesIBA 06/2021 - 10/2020
2	Cancer VaccinesIBA 12/2020 - 11/2020
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019 - 11/2018
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2019 - 11/2018
2	CateninsIBA 01/2018 - 06/2015
2	Interferon-gamma (Interferon, gamma)IBA 01/2017 - 09/2016
2	dabrafenibIBA 07/2016 - 03/2015
2	trametinibIBA 07/2016 - 03/2015
2	EWS-FLI fusion proteinIBA 10/2005 - 06/2005
1	Temozolomide (Temodar)FDA LinkGeneric 06/2023
1	B7-H1 AntigenIBA 01/2023
1	Death Domain ReceptorsIBA 10/2022
1	CTLA-4 AntigenIBA 10/2022
1	Therapeutic UsesIBA 01/2022
1	Immunologic Factors (Immunomodulators)IBA 06/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2021
1	Monoclonal AntibodiesIBA 04/2020
1	Interleukin-2 (IL2)IBA 01/2020
1	KPT-9274IBA 01/2020
1	bempegaldesleukinIBA 01/2020
1	p21-Activated KinasesIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2019
1	EpitopesIBA 11/2018
1	Antineoplastic Agents (Antineoplastics)IBA 01/2018
1	Immunoglobulin G (IgG)IBA 09/2017
1	Interferon gamma ReceptorIBA 01/2017
1	CarcinogensIBA 10/2016
1	Janus Kinase 1IBA 09/2016
1	Interferon Receptors (Interferon Receptor)IBA 09/2016
1	Janus Kinase 2IBA 09/2016
1	Mitogen-Activated Protein KinasesIBA 03/2016
1	Macrophage Colony-Stimulating Factor Receptor (Receptor, Macrophage Colony Stimulating Factor)IBA 05/2015
1	VemurafenibIBA 05/2015
1	pexidartinibIBA 05/2015
1	Macrophage Colony-Stimulating FactorIBA 05/2015
1	Cetuximab (Erbitux)FDA Link 08/2011
1	ParaffinIBA 08/2011
1	ErbB Receptors (EGF Receptor)IBA 08/2011
1	Epidermal Growth Factor (EGF)IBA 08/2011
1	Formaldehyde (Formol)FDA Link 08/2011
1	Transferrin Receptors (Transferrin Receptor)IBA 10/2005
1	Small Interfering RNA (siRNA)IBA 10/2005
1	Transferrin (beta 2 Transferrin)IBA 10/2005
1	CyclodextrinsIBA 10/2005
1	Tetracycline (Achromycin)FDA LinkGeneric 06/2005

Therapy/Procedure

34	Therapeutics 01/2024 - 10/2005
16	Immunotherapy 06/2023 - 07/2014
2	Neoadjuvant Therapy 03/2023 - 08/2011
1	Aftercare (After-Treatment) 01/2024
1	AT protocol 11/2021
1	Intravenous Administration 07/2019
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2019
1	Drug Therapy (Chemotherapy) 01/2018